The US Centers for Medicare and Medicaid Services (CMS) released its national coverage determination (NCD) for anti-amyloid antibodies on 11 January, just before Eli Lilly and Company CEO David Ricks took the virtual stage at the J.P. Morgan Healthcare Conference. (Also see "Medicare Draft NCD For Alzheimer's Drugs: When 'Reasonable And Necessary' And 'Safe And Effective' No Longer Align" - Pink Sheet, 12 January, 2022.)
The decision has an immediate impact on Biogen, Inc./Eisai Co., Ltd.'s approved product Aduhelm (aducanumab), but Lilly is...





